Welcome to our dedicated page for Allovir news (Ticker: ALVR), a resource for investors and traders seeking the latest updates and insights on Allovir stock.
The AlloVir, Inc. (ALVR) news page on Stock Titan aggregates company communications and third-party coverage related to its activities as an allogeneic T cell immunotherapy developer and its planned merger with Kalaris Therapeutics, Inc. AlloVir describes itself as a late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in immunocompromised pediatric and adult patients. Its disclosures highlight an off-the-shelf, allogeneic virus-specific T cell platform and a pipeline led by the multi-virus-specific T cell therapy posoleucel.
Readers following ALVR news can find updates on clinical trial progress and outcomes, including Phase 2 and Phase 3 studies of posoleucel in allogeneic hematopoietic cell transplant recipients and adult kidney transplant recipients with BK viremia. Company releases have discussed prevention and treatment trials targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6, and JC virus, as well as early-stage work on ALVR106 for respiratory viruses and ALVR107 for chronic hepatitis B infection.
News items also cover strategic and corporate developments. AlloVir has reported discontinuation of its three Phase 3 posoleucel studies after pre-planned futility analyses, along with a shift toward capital preservation and review of strategic alternatives. Subsequent announcements describe a definitive all-stock merger agreement with Kalaris Therapeutics, stockholder approval of that merger, and expectations that the combined company will operate as Kalaris Therapeutics, Inc. and trade on Nasdaq under the ticker KLRS, subject to customary closing conditions.
In addition, the ALVR news feed may include information on financings, investor conference participation, and regulatory designations such as RMAT, Orphan Drug, and PRIME status for posoleucel. Investors and researchers can use this page to monitor how AlloVir’s virus-specific T cell programs and its transition toward a retina-focused combined company with Kalaris are described over time.
AlloVir announced final data from a Phase 2 study of posoleucel, a T-cell therapy targeting six viral infections in allo-HCT recipients. The results showed that 88% of patients remained free from clinically significant infections by Week 14, despite high rates of viral reactivation. Biomarker analyses revealed a link between viral control and the expansion of virus-specific T cells. The company is advancing into a global Phase 3 trial and will host an investor webcast on December 14, 2022, to discuss its findings.
AlloVir, a late-stage allogeneic T-cell immunotherapy company, announced that CEO Diana Brainard will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference in New York on November 29, 2022, at 12:00 p.m. ET. Investors can access a live webcast and an archived replay through the company's website. AlloVir focuses on restoring immunity against viral diseases in patients with weakened immune systems, utilizing its proprietary technology for broader treatment and prevention of viral infections.
AlloVir, Inc. (NASDAQ: ALVR) announced that final data from its Phase 2 study of posoleucel to prevent clinically significant infections post-allo-HCT will be presented at the 64th American Society of Hematology Annual Meeting in New Orleans from December 10-13, 2022. Posoleucel is designed to combat multiple life-threatening viral infections in patients with weakened immune systems. Early results have prompted AlloVir to initiate a global Phase 3 study in multi-virus prevention, reflecting strong interest from leading transplant centers.
AlloVir, Inc. (Nasdaq: ALVR) reported Q3 2022 financial results, highlighting ongoing Phase 3 trials of posoleucel for preventing life-threatening viral infections in patients post-allogeneic stem cell transplant. Research and development expenses decreased to $30 million from $33.1 million year-over-year, while general and administrative costs remained stable at $12.9 million. The company holds $264.1 million in cash and equivalents. AlloVir anticipates releasing final data from its Phase 2 multi-virus prevention study by year-end and plans a webcast on December 14.
AlloVir, Inc. (NASDAQ: ALVR), a late-stage allogeneic T-cell immunotherapy company, announced that CEO Diana Brainard will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York on Wednesday, September 14, 2022, at 12:20 p.m. ET. A live webcast and replay will be available on AlloVir’s website. The company focuses on restoring immunity against viral diseases in patients with weakened immune systems using innovative T-cell therapies. For more details, visit AlloVir's website.
AlloVir, Inc. (Nasdaq: ALVR) reported financial results for Q2 2022, highlighting ongoing Phase 3 trials for its lead candidate, posoleucel. The company raised $126.6 million through a direct offering to support these trials and global regulatory submissions. Preliminary Phase 2 data for posoleucel shows promise in preventing viral infections in transplant patients, enhancing its potential market impact. However, the company reported a net loss of $44.6 million for the quarter, and cash reserves decreased to $172.7 million, raising concerns about future financial sustainability.
AlloVir (ALVR) announced a registered direct offering to sell 27,458,095 shares at $4.61 each, raising approximately $126.6 million, expected to close around July 28, 2022. The proceeds will fund ongoing Phase 3 trials for posoleucel, aimed at treating severe infections in immunocompromised patients. AlloVir plans to use the funds for trial completion, regulatory submissions, and R&D. As of June 30, 2022, the company had $172.7 million in cash. The offering is made without an underwriter and involves participation from new and existing investors, including Kite (GILD).
AlloVir (ALVR) announced successful completion of Phase 2 study enrollment for posoleucel, a T-cell therapy aimed at treating BK viremia in kidney transplant patients. Importantly, posoleucel was well-tolerated, showing no graft rejection cases. Preliminary data indicated a significant decline in median BK viral load among patients after 12 weeks of dosing. The study is recognized as the largest of its kind in solid organ transplant patients. Unblinded results from all 61 participants are expected in Q1 2023.
AlloVir has initiated a registrational study for posoleucel to prevent six viral infections in high-risk allo-HCT patients, with enrollment ongoing in the U.S., Western Europe, and Asia. The FDA has granted RMAT designation for this indication, targeting a patient population of 40,000 annually. The company has also progressed three Phase 3 studies and a Phase 2 trial for ALVR106. Financially, for Q1 2022, AlloVir reported a net loss of $43.9 million and operating expenses of $43.2 million, while cash and equivalents stood at $201.4 million, down from $248.1 million at the end of 2021.
AlloVir has received its third Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its lead product, posoleucel, aimed at preventing significant infections from six viruses in high-risk patients post-allogeneic hematopoietic cell transplant (allo-HCT). This designation acknowledges the therapy's potential to address unmet medical needs. Initial data from a Phase 2 study shows a favorable safety profile, with few clinically significant infections among participants. AlloVir anticipates final Phase 2 results by year-end.